Europe’s biotech frontier: New ERC report charts breakthrough potential and barriers
Europe’s frontier research is pushing into new territory across biotechnology, from synthetic biology and gene editing to AI‑enabled life‑science research, engineered living materials and new forms of biomanufacturing. A new analysis by the ERC, including a survey of biotechnology researchers it has funded, highlights both the strength of this research base and the challenges of moving promising discoveries towards application.
The survey, conducted in May 2026, identifies five key areas where challenges remain: support for frontier biotechnology research; funding gaps between early-stage discovery and ERC Proof of Concept grants; commercialisation and scale-up; stronger innovation ecosystems; and governance and policy frameworks.
The analysis also underlines a defining strength of frontier research: not every discovery needs an immediate application. Around 22 % of projects remain far from practical use. By supporting curiosity-driven research, the ERC fosters new knowledge, methods and technologies whose applications may emerge only in the longer term.
In the report’s foreword, former ERC Scientific Council member Geneviève Almouzni and current member Dirk Inzé wrote: ‘Frontier research is where this future takes shape long before it is visible elsewhere: today’s investigator‑driven exploration of living systems is tomorrow’s therapy, crop, material or industrial process.’
Looking towards 2030
ERC biotechnology researchers also identified the technologies they expect to have the greatest impact on biotechnology by 2030. These include:
- AI-enabled life-science data mining (85 %),
- mRNA vaccines (82 %),
- omics technologies (78 %),
- tissue engineering (77 %) and
- CRISPR-Cas (76 %).
Other technologies highlighted include CAR-based therapies, engineered living materials and synthetic cells, and pluripotent stem cells.
Together, the findings illustrate the breadth and dynamism of Europe’s biotechnology research frontier, while highlighting the conditions that can help promising discoveries progress towards further development and application.
A broad and diverse frontier research base
The ERC awarded € 4.09 billion in funding to biotechnology research between 2014 and 2023, supporting 2 416 projects in 28 countries. These projects accounted for 21 % of all ERC projects funded during this period.
The portfolio spans fields from medical biotechnology to industrial, agricultural, environmental and blue biotechnology, as well as emerging areas including synthetic biology, bio-based technologies, engineered living materials, nanotechnology and environmental monitoring.
Some research results have moved beyond the original research project towards further development and innovation. Biotechnology projects received 531 ERC Proof of Concept grants between 2014 and 2023, representing 30 % of all ERC Proof of Concept grants during the period.
Building on these, 24 ERC-funded projects went on to receive a total of 25 European Innovation Council (EIC) Transition grants. Within the portfolio, 211 researchers have filed patents, and 72 spin-off companies have been launched.
